Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Secondhand smoke is associated with more frequent hospitalizations in children with sickle cell disease
source: American Journal of Hematology
year: 2016
authors: Sadreameli SC, Eakin MN, Robinson KT, Alade RO, Strouse JJ
summary/abstract:Tobacco smoke exposure has been associated with more frequent hospitalizations in children with sickle cell disease (SCD), but previous studies have not quantified the exposure by objective methods. We enrolled 50 children and young adults with SCD in a retrospective and prospective cohort study and quantified tobacco smoke exposure by objective (salivary cotinine) and survey measures. We used a multivariable negative binomial regression model to evaluate the association between salivary cotinine and hospital admissions. Forty-five percent (22/49) of participants had significant elevation of salivary cotinine (≥ 0.5 ng/ml). The incidence risk ratio (IRR) for hospital admission for those with elevated cotinine was 3.7 (95% CI 1.8-8). Those exposed to secondhand smoke but not primary smokers (cotinine between 0.5 and 10 ng/ml) had a similarly increased risk of hospitalization [IRR 4.3 (95% CI 1.8-10)]. We show that an objective measure of tobacco smoke exposure, salivary cotinine, is strongly associated with the rate of hospital admissions in children and young adults with SCD. This association underscores the importance of screening for tobacco smoke exposure in people with SCD. Further investigation is warranted to determine the mechanisms of and to evaluate interventions to decrease tobacco smoke exposure.
organization: Johns Hopkins University, BaltimoreDOI: 10.1002/ajh.24281
read more full text
Related Content
-
Sickle Cell DiseaseWhat is sickle cell disease? Sickle cel...
-
Isaac Odame, MB ChB, MRCP, FRCPath, FRCPCH, FRCPCDr. Isaac Odame is a staff physician and...
-
Enrico M. Novelli, MD, MSDr. Novelli obtained his MD degree from ...
-
Ann & Robert H. Lurie Children’s Hospital of ChicagoThe Sickle Cell Disease Program at Ann &...
-
Gene-Therapy Company Crispr Drops as FDA Puts Trial on HoldCrispr Therapeutics AG plunged after the...
-
MARAC Statement: Update About COVIDThe worldwide pandemic of COVID-19 (SARS...
-
The Comprehensive Sickle Cell Center at Children’s Hospital of PhiladelphiaThe Comprehensive Sickle Cell Center at ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.